alcobra pharma home about our company management directors pipeline abusedeterrent amphetamine immediaterelease adair for adhd metadoxine extended release mdx for fragile x syndrome scientific posters  publications investors corporate governance financial information stock information investor faqs contact news  events contact alcobra relentlessly pursues creative unbeaten paths for the identification development and commercialization of therapeutics for impairing cns disorders we are committed to developing safe and effective products for the treatment of cognitive disorders includingadhd and fragile x syndrome view our corporate presentation previous next copyright  alcobra pharma alcobra ltd press releases home about our company management directors pipeline abusedeterrent amphetamine immediaterelease adair for adhd metadoxine extended release mdx for fragile x syndrome scientific posters  publications investors corporate governance financial information stock information investor faqs contact news  events contact press releases year all years         all releases jun   alcobra updates on its review of strategic alternatives tel aviv israel june   globe newswire  alcobra ltd nasdaqadhd an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical needs today announced that its board of directors is conducting a process to explore and review a range of strategic alternatives    continue reading → jun   alcobra announces cooperation agreement with brosh group and board additions company adds two directors to the board company to continue strategic alternatives process to maximize value for all shareholders tel aviv israel june   globe newswire  alcobra ltd nasdaqadhd an emerging pharmaceutical company focused on the development o    continue reading → may   alcobra announces first quarter  financial results and provides corporate update tel aviv israel may   globe newswire  alcobra ltd nasdaqadhd today announced financial results for the three months ended march   and provided a corporate update first quarter and recent corporate updates alcobra recently announced that dr yaron     continue reading → may   alcobra announces leadership update dr yaron daniely to step down as chief executive officer effective may   david baker named interim chief executive officer dr daniely to remain on board of directors and be appointed chairman tel aviv israel may   globe n    continue reading → may   alcobra provides update on cancellation of extraordinary meeting called by brosh group tel aviv israel may   globe newswire  alcobra ltd nasdaqadhd an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical needs today announced that it has reached an agreement the agreement with brosh capital lp and certain of its affiliates th    continue reading → apr   alcobra provides update on request for extraordinary general meeting brosh capitals request does not comply with alcobras articles of association company addresses brosh capitals misinformed views   tel aviv israel april   globe newswire  alcobra ltd nasdaqadhd an emerging pharmaceutical company focused on the deve    continue reading → mar   alcobra ltd to participate in upcoming healthcare conferences tel aviv israel march   globe newswire  alcobra ltd nasdaqgmadhd an emerging pharmaceutical company focused on the development of new medications to treat central nervous system and cognitive disorders today announced that management will participate in two upcoming investor healthcare conferences during march     continue reading → mar   alcobra to host investor forum and webcast on march  in new york city tel aviv israel march   globe newswire  alcobra ltd nasdaqgmadhd an emerging pharmaceutical company focused on the development of new medications to treat central nervous system and cognitive disorders today announced that it will host an investor forum on tuesday march   from  am est in     continue reading → feb   alcobra announces fourthquarter and fullyear  financial results and provides corporate update conference call  webcast february th at  am eastern time am pacific time tel aviv israel feb   globe newswire  alcobra ltd nasdaqadhd an emerging pharmaceutical company focused on the development of new medications to treat cns and cognitive disorders today announced    continue reading → feb   alcobra ltd to release fiscal  financial results and participate at the bio ceo  investor conference in new york tel aviv israel feb   globe newswire  alcobra ltd nasdaqadhd an emerging pharmaceutical company focused on the development of new medications to treat cns and cognitive disorders today announced that it will report its financial results for the year ended december   on wednesday february  at  am     continue reading → feb   alcobra reports on productive fda meeting for new lead product candidate for adhd preind meeting held on alcobras proprietary abusedeterrent amphetamine immediate release adair product candidatemeeting defined a b development path to be funded with existing cash balance and targe    continue reading → jan   alcobra reports phase  clinical trial of mdx in adults with adhd missed primary endpoint tel aviv israel jan   globe newswire  alcobra ltd nasdaqadhd an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders including attention deficit hyperactivity disorder adhd and fragile x syndrome today reported the topline results from me    continue reading → jan   alcobra provides update on recent fda meeting and path forward for mdx clinical development program  alcobra and fda agree on review of available data from the phase  measure study in a future nda submission topline results from the measure study to be reported in the coming weeks fda to modify clinical hold from full to partial to allow the conduct of a phase i safety study management to hold a confere    continue reading → dec   alcobra updates on recent fda meeting tel aviv israel dec   globe newswire  alcobra ltd nasdaqadhd an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders including attention deficit hyperactivity disorder adhd and fragile x syndrome announced today that it recently held a productive face    continue reading → nov   alcobra announces third quarter  financial results and provides corporate update conference call  webcast november th at  am eastern time am pacific time tel aviv israel nov   globe newswire  alcobra ltd nasdaqadhd an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders incl    continue reading → nov   alcobra ltd to participate in upcoming healthcare conferences tel aviv israel nov   globe newswire  alcobra ltd nasdaqadhd an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders including attention deficit hyperactivity disorder adhd and fragile x syndrome today announced that management will participate in sever    continue reading → nov   alcobra ltd to release third quarter financial results and host corporate update conference call  webcast on november  tel aviv israel nov   globe newswire  alcobra ltd nasdaqadhd an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders including attention deficit hyperactivity disorder adhd and fragile x syndrome today announced that it will report its fina    continue reading → oct   update from alcobra on recent fda communications tel aviv israel oct   globe newswire  alcobra ltd nasdaqadhd an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders including attention deficit hyperactivity disorder adhd and fragile x syndrome announced today that it has received the written full cl    continue reading → sep   alcobra announces ind clinical hold affecting the mdx phase iii measure study tel aviv israel sept   globe newswire  alcobra ltd nasdaqgmadhd an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders including attention deficit hyperactivity disorder adhd and fragile x syndrome today announced that it has received verbal notice fr    continue reading → aug   alcobra announces second quarter  financial results and provides corporate update tel aviv israel aug   globe newswire  alcobra ltd nasdaqadhd an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders including attention deficit hyperactivity disorder adhd and fragile x syndrome today announced financial results for the three and six     continue reading →  add release to briefcase search for investor home press releases events in the news copyright  alcobra pharma alcobra ltd about alcobra home about our company management directors pipeline abusedeterrent amphetamine immediaterelease adair for adhd metadoxine extended release mdx for fragile x syndrome scientific posters  publications investors corporate governance financial information stock information investor faqs contact news  events contact about alcobra our company we are a publicly traded emerging pharmaceutical company nasdaq adhd primarily focused on the development and commercialization of novel treatments for cns and cognitive disorders such as adhd and fragile x syndrome our vision alcobra an israeli corporation relentlessly pursues creative unbeaten paths for the identification development and commercialization of therapeutics for impairing cns disorders we are committed to becoming a leading global player in the pharmaceutical industry through disruptive efficiency and innovation our strategy our objective is to develop and commercialize novel proprietary pharmaceutical products for treatment of central nervous system disorders particularly cognitive dysfunctions     search for copyright  alcobra pharma alcobra ltd investor faqs home about our company management directors pipeline abusedeterrent amphetamine immediaterelease adair for adhd metadoxine extended release mdx for fragile x syndrome scientific posters  publications investors corporate governance financial information stock information investor faqs contact news  events contact investor faqs display all answers show all hide all what is alcobras business focus alcobra ltd is a clinicalstage biopharmaceutical company primarily focused on the development and commercialization of our proprietary drug metadoxine extended release mdx to treat attention deficit hyperactivity disorder adhd and other cognitive disorders where can i find additional information about alcobra information can be accessed directly through the companys web site httpwwwalcobrapharmacom annual f reports quarterly reports filed in a k and other filings with the sec can be accessed directly through the company web site or through the securities and exchange commission at wwwsecgov where is alcobra ltd headquartered azrieli triangle building th floor  derech menachem begin tel aviv  israel what is alcobras stock symbol alcobra common stock trades under the symbol “adhd” where does alcobras common stock trade shares of alcobra trades on the nasdaq global market when did alcobra complete its initial public offering ipo and what was the offering price alcobra completed its initial public offering on may   at a price of  per share how many common share of alcobra ltd are outstanding the total number of shares outstanding for alcobra can be found in the company’s filings with the sec at httpwwwalcobrapharmacomseccfm when is the fiscal year end for alcobra ltd alcobra’s fiscal year end is december st how do i invest in alcobra ltd interested investors may purchase shares of alcobra through any registered broker does alcobra offer a direct stock purchase plan no alcobra does not offer a direct stock purchase plan at this time does alcobra ltd pay a dividend alcobra does not currently pay a dividend to its stockholders who is alcobras transfer agent and how does a registered shareholder contact the agent regarding account information continental stock transfer  trust company mailovernight address  battery place th floor new york ny  phone   who is alcobras independent auditor alcobra’s independent auditor is kost forer gabbay  kasierer a member of ernst  young global how do i contact investor relations for investor relations please contact the following individuals investors contacts debbie kaye alcobra investor relations tel  or  email debbiealcobrapharmacom   do you have another question that hasnt been answered please submit your question using the form below  required fields name    email    affiliation  please select investor analyst business partner patient or caregiver healthcare professional potential investor other   subject    comments    type in number      this helps alcobra ltd prevent automated submissions   javascript is not enabled with javascript enabled this page will display content dynamically search for investor home corporate governance corporate governance overview directors clinical advisory board management contact the board financials and filings press releases sec filings events financial information financial information overview annual reports corporate presentation quarterly results key ratios stock information stock information overview historic stock lookup investment calculator analysts investor faqs contact corporate ppt corporate ppt shareholder briefcase shareholder briefcase email alerts email alerts download library download library snapshot snapshot rss news feeds rss news feeds copyright  alcobra pharma alcobra ltd corporate governance home about our company management directors pipeline abusedeterrent amphetamine immediaterelease adair for adhd metadoxine extended release mdx for fragile x syndrome scientific posters  publications investors corporate governance financial information stock information investor faqs contact news  events contact corporate governance the board of directors of alcobra ltd the company sets high standards for the companys employees officers and directors implicit in this philosophy is the importance of sound corporate governance it is the duty of the board of directors to serve as a prudent fiduciary for shareholders and to oversee the management of the companys business to fulfill its responsibilities and to discharge its duty the board of directors follows the procedures and standards that are set forth in these guidelines these guidelines are subject to modification from time to time as the board of directors deems appropriate in the best interests of the company or as required by applicable laws and regulations document view code of business conduct and ethics    kb charter of the audit committee   kb charter of the compensation committee   kb  add file to briefcase committee composition below is a summary of our committee structure and membership information to read more about any of the committees click on committee names in the chart below display all bios   audit nominating and governance compensation howard b rosen       director elected  howard b rosen has served on our board since the closing of our initial public offering in may  and as our chairman since february  since  mr rosen has served as a consultant to several companies in the biotechnology industry he has also served as a lecturer at stanford university in chemical engineering since  and in management since  mr rosen has served  as a director at acelrx pharmaceuticals nasdaq acrx inc a company developing products for pain relief since  as its interim ceo from april  to march  and from april  to march  as its ceo mr rosen served as interim president and chief executive officer of pearl therapeutics inc a company focused on developing combination therapies for the treatment of highly prevalent chronic respiratory diseases from june  to march  from  to  mr rosen was vice president of commercial strategy at gilead sciences inc a biopharmaceutical company from  until  mr rosen was president of alza corporation a pharmaceutical and medical systems company that merged with johnson  johnson a global healthcare company in  prior to that from  until  mr rosen held various positions at alza corporation mr rosen is also a member of the board of directors a number of private biotechnology companies as follows entrega inc and kala pharmaceuticals inc previously mr rosen served on the board of directors of a number of public companies as follows pharsight corporation a company focused on providing software products and consulting services to biopharmaceutical companies that was acquired by tripos international in  and cotherix inc a biopharmaceutical company that was acquired by actelion pharmaceuticals ltd in  mr rosen holds a bs in chemical engineering from stanford university an ms in chemical engineering from the massachusetts institute of technology and an mba from the stanford graduate school of business joao siffert md       director elected  dr joao siffert joined our board in july  dr joao siffert  is currently the chief medical officer nestlé health science since august  and till  dr siffert has led the research and development organization at avanir pharmaceuticals inc a specialty pharmaceutical company focused on development and commercialization of neurology products dr siffert is currently the executive vice president rd and chief medical officer responsible for rd regulatory quality cmc and commercial supply as well as medical affairs and pharmacovigilance prior to joining avanir dr siffert served as vice president and chief medical officer at ceregene inc a biotechnology company focused on the development of neurotrophic gene therapies for alzheimer’s and parkinson’s diseases from september  to august  prior to his work at ceregene dr siffert served as the chief medical officer at avera pharmaceuticals a specialty pharmaceutical company from may  to september  prior to joining avera dr siffert held positions with pfizer from february  to may  first as a medical director for relpax and subsequently as the worldwide medical team leader of lyrica and neurontin focusing in areas of pain and epilepsy prior to pfizer dr siffert held academic positions at beth israel medical center ny where he served as director of the adult neurooncology program and albert einstein college of medicine where he was an assistant professor of neurology dr siffert completed residencies in pediatrics at new york university school of medicine and in neurology at harvard medical school dr siffert was certified by the american board of neurology and psychiatry in  he holds an md from the university of sao paulo school of medicine brazil as well as an mba from columbia university graduate school of business daniel e geffken     director elected  daniel e geffken has served on our board since our initial public offering in may  since october  he has been managing director of danforth advisors llc a management consulting firm that provides financial and strategic support to emerging life science companies  mr geffken has also been the chief financial officer or chief operating officer of eight companies four of which were us public reporting companies and six of which were life science companies  he has a bs in economics from the wharton school university of pennsylvania and a mba from harvard business school orli tori     director orli tori joined our board in august  ms tori is an experienced executive with over  years of practice in leading teams towards their goals and beyond since  and until recently ms tori served as chief executive officer of birad ltd managing bar ilan universitys ip and commercialization efforts as well as all research collaborations with industry during her tenure the company built a diverse portfolio of companies based on university ip before joining birad ms tori spent  years in the pharmaceutical industry fulfilling different positions including general manager of neopharm israel ltd from  through   million revenues and svp corporate bd of the neopharm group and was responsible for the group overall corporate development activities including structuring negotiating and closing transactions ms tori serves as a board member at collplant ltd clpt and is former chairperson of the israeli technology transfer organization ms tori obtained her msc in microbiology cum laude and bsc in life sciences at tel aviv university in tel aviv israel and graduated the executive program for senior business managers at the tel aviv university school of business aharon schwartz phd       director dr aharon schwartz joined our board as chairman in january  serving as our chairman until february  he retired from teva pharmaceutical industries ltd where he served in a number of positions from  through  the most recent being vice president head of teva innovative ventures from  he is also the chairman of the board of directors of biolinerx ltd and director several other biotechnology companies dr schwartz received his phd in organic chemistry from the weizmann institute his msc in organic chemistry from the technion institute of technology and a bsc in chemistry and physics from the hebrew university of jerusalem he has received a second phd in the history and philosophy of science from the hebrew university of jerusalem arieh ben yosef   director arieh ben yosef joined our board in may  mr ben yosef is currently the chief executive officer at herd moonitor ltd mr ben yosef has served as a director of insuline medical ltd tase insl since october  which is focused on improving the performance of current insulin treatment methods from august  to july  mr ben yosef served as a director of microwave networks inc a provider of microwave communications products and services from  to  mr ben yosef was employed by teledata networks ltd a global provider of access network products and solutions for telecom service providers in the positions of chief financial officer executive vice president for finance  operations and later on as the general manager of the company from  to  mr ben yosef served as the president of elisra inc and from  to  as the cfo of tadiran electronic industries inc mr ben yosef holds a mba from the hebrew university of jerusalem ofer segev   director ofer segev has served as a director since august  mr segev has been chief financial officer and chief operating officer at algosec inc a network security policy management solutions provider since february  mr segev has over  years of management experience in the hightech and services sectors previously he served as the vice president of finance and chief financial officer of audiocodes limited a communications company traded on the nasdaq global select market from november  through april  prior to that mr segev served as the chief executive officer and as a director of ness technologies srl from  to  and as its chief financial officer from  to  mr segev also serves as a director of varonis system inc mr segev holds a ba in economics and accounting from barilan university in israel and has studied at the kellogg school of management at northwestern university amir efrati       director mr efrati joined our board in june  mr efrati is the founder managing partner and cio of brosh capital partners founded in  in israel prior to that from  he was the managing partner of the dragon variation fund mr efrati was a sector specialist at jck partners and prior to that at elm ridge capital management in new york city previously he was an investment banker at morgan stanley in new york city and a management consultant in israel he has a bachelor’s degree in economics magna cum laude from the tel aviv university and an mba with distinction from columbia university new york yuval yanai       director mr yanai joined our board in june  mr yanai serves as an external director of checkcap ltd an israeli company whose shares are listed on the nasdaq global market mr yanai also serves as an external director of medical compression systems dbn ltd and call biotechnology israeli companies whose shares are listed on the tel aviv stock exchange mr yanai also serves as an external director of hadassah medical center as an external director of standard  poor’s maalot and as a director of compulab ltd and efranat ltd mr yanai also acts as the chairman of endobetix ltd and as the chairman of the israeli fund for unicef from september  until march  mr yanai served as given imaging’s chief financial officer and from october  until june  mr yanai served as a director of citycon oyj and macrocure ltd mr yanai holds a bsc degree in accounting and economics from telaviv university  chair of the board  chair  member search for investor home corporate governance corporate governance overview directors clinical advisory board management contact the board financials and filings press releases sec filings events financial information financial information overview annual reports corporate presentation quarterly results key ratios stock information stock information overview historic stock lookup investment calculator analysts investor faqs contact corporate ppt corporate ppt shareholder briefcase shareholder briefcase email alerts email alerts download library download library snapshot snapshot rss news feeds rss news feeds copyright  alcobra pharma alcobra ltd stock information home about our company management directors pipeline abusedeterrent amphetamine immediaterelease adair for adhd metadoxine extended release mdx for fragile x syndrome scientific posters  publications investors corporate governance financial information stock information investor faqs contact news  events contact stock information alcobra pharma nasdaq adhd  am et on jul   last price change open day high week high          volume previous close day low week low     javascript is disabled please click here to view our stock chart   sign up for email alerts the stock information provided is for informational purposes only and is not intended for trading purposes the stock information is provided by esignal stock charts are provided by nasdaq omx both third party services and alcobra ltd does not maintain or provide information directly to this service stock information is delayed approximately  minutes search for investor home corporate governance corporate governance overview directors clinical advisory board management contact the board financials and filings press releases sec filings events financial information financial information overview annual reports corporate presentation quarterly results key ratios stock information stock information overview historic stock lookup investment calculator analysts investor faqs contact corporate ppt corporate ppt shareholder briefcase shareholder briefcase email alerts email alerts download library download library snapshot snapshot rss news feeds rss news feeds copyright  alcobra pharma alcobra ltd products home about our company management directors pipeline abusedeterrent amphetamine immediaterelease adair for adhd metadoxine extended release mdx for fragile x syndrome scientific posters  publications investors corporate governance financial information stock information investor faqs contact news  events contact products search for abusedeterrent amphetamine immediaterelease adair for adhd metadoxine extended release mdx for fragile x syndrome scientific posters  publications copyright  alcobra pharma alcobra  wikipedia alcobra from wikipedia the free encyclopedia jump to navigation search this article may rely excessively on sources too closely associated with the subject potentially preventing the article from being verifiable and neutral please help improve it by replacing them with more appropriate citations to reliable independent thirdparty sources october  learn how and when to remove this template message alcobra ltd type public company traded as nasdaq adhd industry pharmaceutical industry headquarters tel aviv israel products metadoxine extended release mdx website wwwalcobrapharmacom alcobra ltd is a public specialty pharmaceutical company the company is focused on the development of new medications to help patients with cognitive disorders including attention deficit hyperactivity disorder adhd and fragile x syndrome alcobra is headquartered in tel aviv israel and also has a us office located outside of philadelphia in plymouth meeting pennsylvania contents  company history  products in development  adhd  fragile x syndrome  references company historyedit alcobra was founded in  in  the company completed an initial public offering ipo and trades under the symbol “adhd” on the nasdaq stock exchange products in developmentedit metadoxine extended release mdx is the company’s lead investigational product candidate metadoxine extended release is a monoamineindependent modulator of gaba gammaaminobutyric acid transmission the mechanism of action does not directly affect dopamine or norepinephrine the compound is not a psychostimulant metadoxine has shown no potential for abuse or addiction in studies completed to date adhdedit alcobra has completed two phase ii trials and one phase iii trial of metadoxine extended release mdx in adults with adhd alcobra has also completed one phase ii adolescent adhd study of metadoxine extended release mdx in mid alcobra began a second phase iii trial of metadoxine extended release mdx in adults with adhd called the measure study fragile x syndromeedit in december  the fda granted orphan drug designation to metadoxine in the treatment of fragile x syndrome in june  alcobra completed a phase ii clinical trial of mdx for the treatment of adolescents and adults with fragile x syndrome in september  the fda granted “fast track” status to metadoxine extended release mdx for fragile x syndrome referencesedit  metadoxine extended release mdx for adult adhd alcobra ltd  retrieved    manor i benhayun r aharonperetz j salomy d weizman a daniely y meggido d newcorn jh biederman j adler la  a randomized doubleblind placebocontrolled multicenter study evaluating the efficacy safety and tolerability of extendedrelease metadoxine in adults with attentiondeficithyperactivity disorder journal of clinical psychiatry  – pmid  doijcpm   manor i rubin j daniely y adler la  attention benefits after a single dose of metadoxine extended release in adults with predominantly inattentive adhd postgrad med  – pmid  doipgm   weisler r adler la rubin j daniely y manor i  a phase  randomized doubleblind placebocontrolled study of metadoxine extended release  mg compared with placebo once daily in  adults with attentiondeficithyperactivity disorder  missing or empty url help  alcobras mdx meets primary endpoint in phase ii safety and tolerability clinical trial in adolescents with adhd alcobra ltd  retrieved    fda grants orphan drug status to metadoxine in fragile x syndrome alcobra ltd  retrieved    alcobra announces results from phase  clinical trial of mdx for fragile x syndrome alcobra ltd  retrieved    fda grants fast track designation to alcobras mdx for fragile x syndrome alcobra ltd  retrieved   v t e israeli companies traded on nasdaq healthcare alcobra biolinerx biondvax pharmaceutical compugen enzymotec given imaging kamada mazor robotics medigus oramed pharmaceuticals perrigo company pluristem therapeutics rewalk robotics rosetta genomics syneron medical communication  networks allot communications alvarion audiocodes b communications ceragon networks dsp group ezchip semiconductor gilat satellite networks internet gold golden lines orckit communications partner communications company radcom radvision rit technologies rr media software attunity bluephoenix solutions bos better online solutions check point software technologies clicksoftware technologies commtouch software cimatron cyberark formula systems  jacada magic software enterprises mind cti nice systems perion network radware sapiens international corporation nv verint systems wix electronics camtek ceva eltek kornit digital mellanox technologies nova measuring instruments orbotech solaredge tower semiconductor security  defense arotech elbit systems ituran location and control magal security systems pointer telocation rada electronic industries tat technologies consumer goods caesarstone sdotyam sodastream international conglomerates ampalamerican israel corporation elbit imaging isramco this company is americanbased but is traded on the tase as a result of a merger with israeli drug maker agis retrieved from httpsenwikipediaorgwindexphptitlealcobraoldid categories pharmaceutical companiespharmaceuticscompanies listed on nasdaqpharmaceutical companies of israelhidden categories pages using web citations with no urlarticles lacking reliable references from october all articles lacking reliable referencespages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  january  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view alcobra  wikipedia alcobra from wikipedia the free encyclopedia jump to navigation search this article may rely excessively on sources too closely associated with the subject potentially preventing the article from being verifiable and neutral please help improve it by replacing them with more appropriate citations to reliable independent thirdparty sources october  learn how and when to remove this template message alcobra ltd type public company traded as nasdaq adhd industry pharmaceutical industry headquarters tel aviv israel products metadoxine extended release mdx website wwwalcobrapharmacom alcobra ltd is a public specialty pharmaceutical company the company is focused on the development of new medications to help patients with cognitive disorders including attention deficit hyperactivity disorder adhd and fragile x syndrome alcobra is headquartered in tel aviv israel and also has a us office located outside of philadelphia in plymouth meeting pennsylvania contents  company history  products in development  adhd  fragile x syndrome  references company historyedit alcobra was founded in  in  the company completed an initial public offering ipo and trades under the symbol “adhd” on the nasdaq stock exchange products in developmentedit metadoxine extended release mdx is the company’s lead investigational product candidate metadoxine extended release is a monoamineindependent modulator of gaba gammaaminobutyric acid transmission the mechanism of action does not directly affect dopamine or norepinephrine the compound is not a psychostimulant metadoxine has shown no potential for abuse or addiction in studies completed to date adhdedit alcobra has completed two phase ii trials and one phase iii trial of metadoxine extended release mdx in adults with adhd alcobra has also completed one phase ii adolescent adhd study of metadoxine extended release mdx in mid alcobra began a second phase iii trial of metadoxine extended release mdx in adults with adhd called the measure study fragile x syndromeedit in december  the fda granted orphan drug designation to metadoxine in the treatment of fragile x syndrome in june  alcobra completed a phase ii clinical trial of mdx for the treatment of adolescents and adults with fragile x syndrome in september  the fda granted “fast track” status to metadoxine extended release mdx for fragile x syndrome referencesedit  metadoxine extended release mdx for adult adhd alcobra ltd  retrieved    manor i benhayun r aharonperetz j salomy d weizman a daniely y meggido d newcorn jh biederman j adler la  a randomized doubleblind placebocontrolled multicenter study evaluating the efficacy safety and tolerability of extendedrelease metadoxine in adults with attentiondeficithyperactivity disorder journal of clinical psychiatry  – pmid  doijcpm   manor i rubin j daniely y adler la  attention benefits after a single dose of metadoxine extended release in adults with predominantly inattentive adhd postgrad med  – pmid  doipgm   weisler r adler la rubin j daniely y manor i  a phase  randomized doubleblind placebocontrolled study of metadoxine extended release  mg compared with placebo once daily in  adults with attentiondeficithyperactivity disorder  missing or empty url help  alcobras mdx meets primary endpoint in phase ii safety and tolerability clinical trial in adolescents with adhd alcobra ltd  retrieved    fda grants orphan drug status to metadoxine in fragile x syndrome alcobra ltd  retrieved    alcobra announces results from phase  clinical trial of mdx for fragile x syndrome alcobra ltd  retrieved    fda grants fast track designation to alcobras mdx for fragile x syndrome alcobra ltd  retrieved   v t e israeli companies traded on nasdaq healthcare alcobra biolinerx biondvax pharmaceutical compugen enzymotec given imaging kamada mazor robotics medigus oramed pharmaceuticals perrigo company pluristem therapeutics rewalk robotics rosetta genomics syneron medical communication  networks allot communications alvarion audiocodes b communications ceragon networks dsp group ezchip semiconductor gilat satellite networks internet gold golden lines orckit communications partner communications company radcom radvision rit technologies rr media software attunity bluephoenix solutions bos better online solutions check point software technologies clicksoftware technologies commtouch software cimatron cyberark formula systems  jacada magic software enterprises mind cti nice systems perion network radware sapiens international corporation nv verint systems wix electronics camtek ceva eltek kornit digital mellanox technologies nova measuring instruments orbotech solaredge tower semiconductor security  defense arotech elbit systems ituran location and control magal security systems pointer telocation rada electronic industries tat technologies consumer goods caesarstone sdotyam sodastream international conglomerates ampalamerican israel corporation elbit imaging isramco this company is americanbased but is traded on the tase as a result of a merger with israeli drug maker agis retrieved from httpsenwikipediaorgwindexphptitlealcobraoldid categories pharmaceutical companiespharmaceuticscompanies listed on nasdaqpharmaceutical companies of israelhidden categories pages using web citations with no urlarticles lacking reliable references from october all articles lacking reliable referencespages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  january  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view alcobra  wikipedia alcobra from wikipedia the free encyclopedia jump to navigation search this article may rely excessively on sources too closely associated with the subject potentially preventing the article from being verifiable and neutral please help improve it by replacing them with more appropriate citations to reliable independent thirdparty sources october  learn how and when to remove this template message alcobra ltd type public company traded as nasdaq adhd industry pharmaceutical industry headquarters tel aviv israel products metadoxine extended release mdx website wwwalcobrapharmacom alcobra ltd is a public specialty pharmaceutical company the company is focused on the development of new medications to help patients with cognitive disorders including attention deficit hyperactivity disorder adhd and fragile x syndrome alcobra is headquartered in tel aviv israel and also has a us office located outside of philadelphia in plymouth meeting pennsylvania contents  company history  products in development  adhd  fragile x syndrome  references company historyedit alcobra was founded in  in  the company completed an initial public offering ipo and trades under the symbol “adhd” on the nasdaq stock exchange products in developmentedit metadoxine extended release mdx is the company’s lead investigational product candidate metadoxine extended release is a monoamineindependent modulator of gaba gammaaminobutyric acid transmission the mechanism of action does not directly affect dopamine or norepinephrine the compound is not a psychostimulant metadoxine has shown no potential for abuse or addiction in studies completed to date adhdedit alcobra has completed two phase ii trials and one phase iii trial of metadoxine extended release mdx in adults with adhd alcobra has also completed one phase ii adolescent adhd study of metadoxine extended release mdx in mid alcobra began a second phase iii trial of metadoxine extended release mdx in adults with adhd called the measure study fragile x syndromeedit in december  the fda granted orphan drug designation to metadoxine in the treatment of fragile x syndrome in june  alcobra completed a phase ii clinical trial of mdx for the treatment of adolescents and adults with fragile x syndrome in september  the fda granted “fast track” status to metadoxine extended release mdx for fragile x syndrome referencesedit  metadoxine extended release mdx for adult adhd alcobra ltd  retrieved    manor i benhayun r aharonperetz j salomy d weizman a daniely y meggido d newcorn jh biederman j adler la  a randomized doubleblind placebocontrolled multicenter study evaluating the efficacy safety and tolerability of extendedrelease metadoxine in adults with attentiondeficithyperactivity disorder journal of clinical psychiatry  – pmid  doijcpm   manor i rubin j daniely y adler la  attention benefits after a single dose of metadoxine extended release in adults with predominantly inattentive adhd postgrad med  – pmid  doipgm   weisler r adler la rubin j daniely y manor i  a phase  randomized doubleblind placebocontrolled study of metadoxine extended release  mg compared with placebo once daily in  adults with attentiondeficithyperactivity disorder  missing or empty url help  alcobras mdx meets primary endpoint in phase ii safety and tolerability clinical trial in adolescents with adhd alcobra ltd  retrieved    fda grants orphan drug status to metadoxine in fragile x syndrome alcobra ltd  retrieved    alcobra announces results from phase  clinical trial of mdx for fragile x syndrome alcobra ltd  retrieved    fda grants fast track designation to alcobras mdx for fragile x syndrome alcobra ltd  retrieved   v t e israeli companies traded on nasdaq healthcare alcobra biolinerx biondvax pharmaceutical compugen enzymotec given imaging kamada mazor robotics medigus oramed pharmaceuticals perrigo company pluristem therapeutics rewalk robotics rosetta genomics syneron medical communication  networks allot communications alvarion audiocodes b communications ceragon networks dsp group ezchip semiconductor gilat satellite networks internet gold golden lines orckit communications partner communications company radcom radvision rit technologies rr media software attunity bluephoenix solutions bos better online solutions check point software technologies clicksoftware technologies commtouch software cimatron cyberark formula systems  jacada magic software enterprises mind cti nice systems perion network radware sapiens international corporation nv verint systems wix electronics camtek ceva eltek kornit digital mellanox technologies nova measuring instruments orbotech solaredge tower semiconductor security  defense arotech elbit systems ituran location and control magal security systems pointer telocation rada electronic industries tat technologies consumer goods caesarstone sdotyam sodastream international conglomerates ampalamerican israel corporation elbit imaging isramco this company is americanbased but is traded on the tase as a result of a merger with israeli drug maker agis retrieved from httpsenwikipediaorgwindexphptitlealcobraoldid categories pharmaceutical companiespharmaceuticscompanies listed on nasdaqpharmaceutical companies of israelhidden categories pages using web citations with no urlarticles lacking reliable references from october all articles lacking reliable referencespages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  january  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view alcobra ltd company profile  bloomberg feedback alcobra ltd public company company profile sector health care industry biotech  pharma subindustry biotech alcobra ltd operates as a biopharmaceutical company the company develops a patented nonstimulant pharmaceutical drug designed to treat attention deficit hyperactivity disorder and other cognitive disorders corporate information address  ehad haam street th floor tel aviv  israel phone  fax  web url wwwalcobrapharmacom board members chairman company board members company daniel geffken promis neurosciences inc yuval yanai compulab ltd howard rosen acelrx pharmaceuticals inc show more from the web press releases alcobra updates on its review of strategic alternatives jun   alcobra announces cooperation agreement with brosh group and board additions jun   alcobra announces first quarter  financial results and provides corporate update may   alcobra announces leadership update may   alcobra provides update on cancellation of extraordinary meeting called by brosh group may   alcobra mails proxy materials for extraordinary general meeting of shareholders apr   exodus capital is summoning an extraordinary general meeting apr   alcobra provides update on request for extraordinary general meeting apr   key executives tomer berkovitz cfocoo david baker interim ceochief commercial ofcr jonathan rubin chief medical officer hanna ron senior vpchemistry manufacturing hagit marchaim senior vpregulatory affairs irena katsman vpfinance shlomi ianovitz dirquality assurance debbie kaye investor relations sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data alcobra ltd  company profile  biocentury publications archives bciq conferences version  free trial  subscribe sign in english   한국어 biocentury menu home  publications  publications home  biocentury bc innovations bc extra bc week in review current issues archives  archives home  basic search advanced search back issues bciq  bciq home  overview pipeline analyst financial analyst company analyst deal analyst conferences  conferences home  newsmakers bio€quity europe future leaders china healthcare summit other industry events elearning  elearning home  videos white papers follow us bciq  company profile bciq overview      settings      support biocentury print this       alcobra ltd nasdaqadhd print preview export bookmark share with colleague general information  location tel aviv israel  region  country israel  business category neurology  year founded   website httpwwwalcobrapharmacom  lead product status phase iii  archive items are loading  financial information  financing summary  financing details  earnings summary  stocks annual chart  pipeline information  pipeline summary  pipeline details  deals information  deals summary  deals details about biocentury company overview management editorial  research contact contact us advertising  sponsorship career opportunities support forgot password customer service reprints faqs products  solutions products overview publications archives bciq conferences elearning rss feeds legal user agreement terms of use privacy policy your california privacy rights use of images follow us what is biocentury biocentury employs a fully integrated multimedia platform — including publications video online data solutions and conferences — to provide its audience with authoritative and uptodate intelligence about corporate strategy partnering emerging technology clinical data public policy and the financial markets sign in free trial   biocentury inc all rights reserved    terms  conditions  privacy policy set email alert dummy alcobra ltd private company information  bloomberg july    am et pharmaceuticals company overview of alcobra ltd snapshot people company overview alcobra ltd a biopharmaceutical company focuses on the development and commercialization of proprietary pharmaceutical products the company’ s product candidates include abusedeterrent amphetamine immediaterelease adair a proprietary abusedeterrent oral formulation of immediaterelease shortacting dextroamphetamine for the treatment of attention deficit hyperactivity disorder adhd and narcolepsy and metadoxine extended release mdx a proprietary oral drug for the treatment of adhd and other cognitive disorders including fragile x syndrome alcobra ltd was founded in  and is headquartered in tel aviv israel azrieli triangle buildingth floor derech menachem begintel aviv  israelfounded in  employees phone     wwwalcobrapharmacom key executives for alcobra ltd mr david c baker interim chief executive officer age  total annual compensation k dr tomer berkovitz chief financial officer and chief operating officer age  total annual compensation k dr jonathan rubin md mba chief medical officer age  total annual compensation k mrs hanna ron msc senior vice president of chemistry manufacturing  controls age  total annual compensation k compensation as of fiscal year  alcobra ltd key developments alcobra updates on review of strategic alternatives jun   alcobra ltd nasdaqgmadhd announced that its board of directors is conducting a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from its development assets and cash resources alcobra has engaged ladenburg thalmann  co inc to act as its strategic financial advisor for this process in conjunction with the exploration of strategic alternatives the company also intends to streamline its operations in order to preserve its capital and cash resources alcobras board has established a special committee to explore and evaluate strategic alternatives potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition merger business combination or other strategic transaction involving the company there can be no assurance however that this process will result in any such transaction alcobra ltd announces board appointments jun   alcobra ltd announced that it has entered into a cooperation agreement with brosh capital partners lp and certain of its affiliates in connection with among other things alcobras  annual general meeting of shareholders pursuant to the cooperation agreement alcobra has appointed two new directors mr amir efrati and mr yuval yanai to the alcobra board of directors effective immediately mr yanai is not affiliated with the brosh group and qualifies as an independent director as of the appointments the alcobra board consists of ten directors mr efrati is the founder managing partner and cio of brosh capital partners founded in  in israel mr yanai serves as an external director of checkcap ltd mr yanai also serves as an external director of medical compression systems dbn ltd and call biotechnology mr yanai also serves as an external director of hadassah medical center as an external director of standard  poor’s maalot and as a director of compulab ltd and efranat ltdmr yanai also acts as the chairman of endobetix ltd and as the chairman of the israeli fund for unicef alcobra ltd announces unaudited consolidated earnings results for the first quarter ended march   may   alcobra ltd announced unaudited consolidated earnings results for the first quarter ended march   for the quarter the company reported loss before taxes on income of  against  a year ago net loss attributable to holders of ordinary shares was  against  a year ago net basic and diluted loss per share was  against  a year ago net cash used in operating activities was  against  a year ago purchase of property and equipment net was  against  a year ago similar private companies by industry company name region abital pharma pipelines ltd middle eastafrica active px ltd middle eastafrica advanced inhalation technology ltd middle eastafrica angio b ltd middle eastafrica antaki center for herbal medicine ltd middle eastafrica recent private companies transactions typedate target mergeracquisition june    request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact alcobra ltd please visit wwwalcobrapharmacom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close alcobra ltd  company profile from hoover’s  db hoovers menu buy reports  lists how it works united states united kingdom   login company people industry search db hoovers company  people  industry login avention onesource is now db hoovers login here for access to db hoovers db datavision db business browser and isell login for customers of hoovers prior to march   login call   chat software by boldchat start free trial call   chat software by boldchat start free trial search the db hoovers database company company people industry home company information company search company overview  profile company profile information for sales preparation marketing contacts competition revenue  financial available products company report pharmaceutical manufacturing industry report competitive reports alcobra ltdcompany information  begin menachem rd floor tel avivjaffa israel † top  competitors johnson  johnson novartis ag shire plc unlock more access to hoover’s build customized email lists  based on your best customer profile learn more about the companies you want to sell to hoover’s has reports on  million companies and  industries  data points are updated each day get real insight written by real people – exclusive research and reviews by our inhouse editorial staff we can deliver our data to your desktop to excel direct to your crm into your custom app or via mobile request your free trial call   today to get started with a free trial   alcobra ltd company profile if it were that easy to treat adhd alcobra would wave a magic wand and say abracadabra instead the israeli company is developing a new type of drug to treat adhd attention deficit hyperactivity disorder the drug candidate mgci differs from traditional pharmaceuticals prescribed to manage adhd in that it is not a stimulant like its wellknown counterparts adderall and ritalin mgci aims to be a safer alternative for patients who cannot tolerate the side effects such as insomnia and high blood pressure associated with stimulants the company teamed up with equity investor teva to complete a phase ii study in adults in  alcobra went public in the us in  † some telephone numbers on the hoover’s site may be on a country’s do not call or do not contact list including but not limited to the united kingdom’s ctps or tps registers it is a legal requirement that companies do not make sales or marketing calls to registered numbers these are central opt out registers whereby corporate subscribers and individuals can register their preference not to receive unsolicited sales and marketing telephone calls by using the information provided on the hoover’s sites as the direct marketer you represent and warrant that you will use such information in compliance with all applicable local state national or international laws and regulations including any local do not call registers or marketing regulations and agree to defend indemnify and hold harmless dun  bradstreet and each of its affiliates in the event your use violates such laws and regulations additional alcobra ltd information sales preparation get relevant industry context to prepare for your next sales call – trends competitors news call prep questions and more marketing campaigns find prospect companies that meet the profile of your best customers to maximize campaign roi strategy  planning identify new market opportunities and new strategies for existing markets credit management  finance determine and track a company’s financial condition related tags tel avivjaffa israel pharmaceutical manufacturing free alerts to changes in your db® credit scores sign up get creditsignal® for free try db credit free for  days get started try db credit free for  days market research amp industry analysis reports  wiseguyreports  page  infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search reset all reset to default price usd  – usd  usd  – usd  usd  – usd  usd  – usd  usd  all price go to published date less than one month less than  month less than  month less than  year all time category clear all aerospace  defense agri  food automotive basic materials company reports consumer goods  retail education energy life sciences manufacturing  construction security  intelligence systems services technology telecom  it show all add category aerospace  defense agri  food automotive basic materials company reports consumer goods  retail education energy life sciences manufacturing  construction security  intelligence systems services technology telecom  it publishers clear all columns dimen research access china management consulting ltd accustream research americas market intelligence asia market info  dev co askci consulting axis research mind azoth analytics beige market intelligence bis report bonafide research and marketing pvt ltd buddecomm cai research cbr pharma insights ccm international limited research ceskaa market research chemreportnet childwise china research and intelligence daedal research darwin health datamarketresearch delveinsight detailed analysis research dpi research enincon eu research euromonitor international feedback consulting gbi research global markets direct global research  data services global wireless research globaldata globalinforesearch grace international group llc heyreport hjresearch homeland security research corporation hongchun icrworld research igate research infoholic research iqi iqi research and consultancy jp research kelly scientific knowledge sourcing intelligence koncept analytics lpi lp information market data forecast market research future marketline marketsizeinfocom mp advisors orion market research paul budde communication politic india proconsulting prof research qyresearch group renub research research facts research nester researchguidance ri technologies rockville research sp consulting sagacious ip signals and systems telecom skbks smart research insights sprout intelligence stanley analysis stellar analytics strategic defence intelligence stratistics mrc stratview research technavio textiles intelligence research the business research company think real timetric tuoda research us market insight wbiss wintergreen research world market intelligence show all add publisher columns dimen research access china management consulting ltd accustream research americas market intelligence asia market info  dev co askci consulting axis research mind azoth analytics beige market intelligence bis report bonafide research and marketing pvt ltd buddecomm cai research cbr pharma insights ccm international limited research ceskaa market research chemreportnet childwise china research and intelligence daedal research darwin health datamarketresearch delveinsight detailed analysis research dpi research enincon eu research euromonitor international feedback consulting gbi research global markets direct global research  data services global wireless research globaldata globalinforesearch grace international group llc heyreport hjresearch homeland security research corporation hongchun icrworld research igate research infoholic research iqi iqi research and consultancy jp research kelly scientific knowledge sourcing intelligence koncept analytics lpi lp information market data forecast market research future marketline marketsizeinfocom mp advisors orion market research paul budde communication politic india proconsulting prof research qyresearch group renub research research facts research nester researchguidance ri technologies rockville research sp consulting sagacious ip signals and systems telecom skbks smart research insights sprout intelligence stanley analysis stellar analytics strategic defence intelligence stratistics mrc stratview research technavio textiles intelligence research the business research company think real timetric tuoda research us market insight wbiss wintergreen research world market intelligence report type upcoming reports published reports all reports continents clear all  global africa asia australia europe north america south america show all add continent africa asia australia europe north america south america regions clear all  asia pacific bric caribbean central america central asia central europe cis east africa east europe european union g g latin america micronesia middle africa middle east nafta northern africa northern europe oceania scandinavia south asia south europe southeast asia southern africa west africa west europe show all add region asia pacific bric caribbean central america central asia central europe cis east africa east europe european union g g latin america micronesia middle africa middle east nafta northern africa northern europe oceania scandinavia south asia south europe southeast asia southern africa west africa west europe countries clear all afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba curacao cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guernsey guinea guineabissau guyana haiti honduras hong kong hungary iceland india indonesia iran iraq ireland isle of man israel italy jamaica japan jersey jordan kazakhstan kenya kiribati kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk north korea northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore sint maarten slovakia slovenia solomon islands somalia south africa south korea spain sri lanka st kitts  nevis st vincent  the grenadines sudan suriname svalbard and jan mayen swaziland sweden switzerland syria tahitifrench polinesia taiwan tajikistan tanzania thailand timorleste togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu vatican city venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe show all add country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba curacao cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guernsey guinea guineabissau guyana haiti honduras hong kong hungary iceland india indonesia iran iraq ireland isle of man israel italy jamaica japan jersey jordan kazakhstan kenya kiribati kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria niue norfolk north korea northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore sint maarten slovakia slovenia solomon islands somalia south africa south korea spain sri lanka st kitts  nevis st vincent  the grenadines sudan suriname svalbard and jan mayen swaziland sweden switzerland syria tahitifrench polinesia taiwan tajikistan tanzania thailand timorleste togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu vatican city venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe purchase premium reports from other market research publishers alcobra ltd adhd  pharmaceuticals  healthcare  deals and alliances profile summary alcobra ltd alcobra is a pharmaceutical company that develops and commercializes proprietary pharmaceutical products the company offers    april  by alcobra ltd adhd  pharmaceuticals  healthcare  deals and alliances profile summary alcobra ltd alcobra is a pharmaceutical company that develops and commercializes proprietary pharmaceutical products and novel treatment    july  by displaying all  report microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft alcobra ltd  netfind content results aol search skip over navigation search the web web web content ltd commodities online  shop ltd commodities catalogs ad · wwwltdcommoditiescom​homeltd shop ltd commodities catalogs  lowest price guaranteed shop todays specials bed  bath sale show now apparel  beauty sale now get deals on toys now housewares  dining sale garden shop  save today buy stock  find it here  searchcom ad · wwwsearchcom​buy stock​now find buy stock here  check out  results now all that you need your finances up to date straight accounting difficult finances adhd stock predictions  flashratingscom ad · flashratingscom all current analyst ratings and price targets for alcobra about us analyst ranking flashratings principles privacy alcobra alcobra ltd is a public specialty pharmaceutical company the company is focused on the development of new medications to help patients with cognitive disorders including attention more go to encyclopedia results from the wowcom content network why alcobra ltd shares temporarily spiked higher  aol  httpswwwaolcomarticlefinancewhyalcobraltd although we dont believe in timing the market or panicking over market movements we do like to keep an eye on big changes  just in case theyre material to  alcobra  wowcom wwwwowcomwikialcobra alcobra ltd is a public specialty pharmaceutical company the company is focused on the development of new medications to help patients with cognitive disorders  yaron danieli news features and videos  wowcom wwwwowcomchannelyarondanieli all the latest news on yaron danieli includes blogs articles opinion yaron danieli videos and more on wowcom  home page  alcobra ltd nasdaq  metadoxine  wowcom wwwwowcomwikimetadoxine metadoxine also known as pyridoxinepyrrolidone carboxylate is a drug used to treat chronic and acute alcohol intoxication  alcobra ltd  alcobra pharmaceuticals adhd  aolcom httpswwwaolcomstockquotesnasdaqalcobrapharmaceuticalsadhd view the basic adhd stock information on aol finance and compare alcobrapharmaceuticals against other companies compugen israeli company  wowcom wwwwowcomwikicompugenisraelicompany compugen israeli company  president  ceo of compugen ltd talks about potential longterm large revenues from licensing of in  alcobra biolinerx biondvax  htb receptor  wowcom wwwwowcomwikihtb involvement of the serotonin htb receptor in cardiac hypertrophy linked to sympathetic stimulation control of interleukin  alcobra ltd   stocks to watch in the changing landscape of adhd drugs httpswwwaolcomarticlefinancestockstowatch certainly alcobra is an interesting stock to watch nonetheless this is a small clinicalstage biotech so an investment here is comparatively risky b communications  wowcom wwwwowcomwikibcommunications operations b communications functions as a holding company of bezeq the israeli telecommunication corp ltd it is a subsidiary of internet gold namely internet gold  caesarstone sdotyam  wowcom wwwwowcomwikicaesarstonesdotyam caesarstone ltd or caesarstone hebrew אבן קיסר ‎‎ even qeysar is a publicly traded company that engages in the manufacture and sale of engineered  ltd commodities online  shop ltd commodities catalogs ad · wwwltdcommoditiescom​homeltd shop ltd commodities catalogs  lowest price guaranteed shop todays specials bed  bath sale show now apparel  beauty sale now get deals on toys now housewares  dining sale garden shop  save today buy stock  find it here  searchcom ad · wwwsearchcom​buy stock​now find buy stock here  check out  results now all that you need your finances up to date straight accounting difficult finances adhd stock predictions  flashratingscom ad · flashratingscom all current analyst ratings and price targets for alcobra about us analyst ranking flashratings principles privacy searches related toalcobra ltd alcobra ltd news alcobra pharmaceuticals news alcobra ltd stock adhd nasdaq alcobra ltd adhd alcobra adhd alcobra pharma alcobra next related searches alcobra ltd news alcobra pharmaceuticals news alcobra ltd stock adhd nasdaq alcobra ltd adhd alcobra adhd alcobra pharma alcobra search the web  aol inc all rights reservedprivacy   terms of use   preferences   contact us   powered by bing™ wowcom  part of the aol search network alcobra ltd adhd  stock predictions  price targets facebook autocomplete demo post a rating  month price target   home trending sign up log in alcobra ltd adhd median target price   upside positive ratings  of  analysts latest  roth capital  buy     view all analyst ratings for adhd » facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising alcobra  wikipedia alcobra from wikipedia the free encyclopedia jump to navigation search this article may rely excessively on sources too closely associated with the subject potentially preventing the article from being verifiable and neutral please help improve it by replacing them with more appropriate citations to reliable independent thirdparty sources october  learn how and when to remove this template message alcobra ltd type public company traded as nasdaq adhd industry pharmaceutical industry headquarters tel aviv israel products metadoxine extended release mdx website wwwalcobrapharmacom alcobra ltd is a public specialty pharmaceutical company the company is focused on the development of new medications to help patients with cognitive disorders including attention deficit hyperactivity disorder adhd and fragile x syndrome alcobra is headquartered in tel aviv israel and also has a us office located outside of philadelphia in plymouth meeting pennsylvania contents  company history  products in development  adhd  fragile x syndrome  references company historyedit alcobra was founded in  in  the company completed an initial public offering ipo and trades under the symbol “adhd” on the nasdaq stock exchange products in developmentedit metadoxine extended release mdx is the company’s lead investigational product candidate metadoxine extended release is a monoamineindependent modulator of gaba gammaaminobutyric acid transmission the mechanism of action does not directly affect dopamine or norepinephrine the compound is not a psychostimulant metadoxine has shown no potential for abuse or addiction in studies completed to date adhdedit alcobra has completed two phase ii trials and one phase iii trial of metadoxine extended release mdx in adults with adhd alcobra has also completed one phase ii adolescent adhd study of metadoxine extended release mdx in mid alcobra began a second phase iii trial of metadoxine extended release mdx in adults with adhd called the measure study fragile x syndromeedit in december  the fda granted orphan drug designation to metadoxine in the treatment of fragile x syndrome in june  alcobra completed a phase ii clinical trial of mdx for the treatment of adolescents and adults with fragile x syndrome in september  the fda granted “fast track” status to metadoxine extended release mdx for fragile x syndrome referencesedit  metadoxine extended release mdx for adult adhd alcobra ltd  retrieved    manor i benhayun r aharonperetz j salomy d weizman a daniely y meggido d newcorn jh biederman j adler la  a randomized doubleblind placebocontrolled multicenter study evaluating the efficacy safety and tolerability of extendedrelease metadoxine in adults with attentiondeficithyperactivity disorder journal of clinical psychiatry  – pmid  doijcpm   manor i rubin j daniely y adler la  attention benefits after a single dose of metadoxine extended release in adults with predominantly inattentive adhd postgrad med  – pmid  doipgm   weisler r adler la rubin j daniely y manor i  a phase  randomized doubleblind placebocontrolled study of metadoxine extended release  mg compared with placebo once daily in  adults with attentiondeficithyperactivity disorder  missing or empty url help  alcobras mdx meets primary endpoint in phase ii safety and tolerability clinical trial in adolescents with adhd alcobra ltd  retrieved    fda grants orphan drug status to metadoxine in fragile x syndrome alcobra ltd  retrieved    alcobra announces results from phase  clinical trial of mdx for fragile x syndrome alcobra ltd  retrieved    fda grants fast track designation to alcobras mdx for fragile x syndrome alcobra ltd  retrieved   v t e israeli companies traded on nasdaq healthcare alcobra biolinerx biondvax pharmaceutical compugen enzymotec given imaging kamada mazor robotics medigus oramed pharmaceuticals perrigo company pluristem therapeutics rewalk robotics rosetta genomics syneron medical communication  networks allot communications alvarion audiocodes b communications ceragon networks dsp group ezchip semiconductor gilat satellite networks internet gold golden lines orckit communications partner communications company radcom radvision rit technologies rr media software attunity bluephoenix solutions bos better online solutions check point software technologies clicksoftware technologies commtouch software cimatron cyberark formula systems  jacada magic software enterprises mind cti nice systems perion network radware sapiens international corporation nv verint systems wix electronics camtek ceva eltek kornit digital mellanox technologies nova measuring instruments orbotech solaredge tower semiconductor security  defense arotech elbit systems ituran location and control magal security systems pointer telocation rada electronic industries tat technologies consumer goods caesarstone sdotyam sodastream international conglomerates ampalamerican israel corporation elbit imaging isramco this company is americanbased but is traded on the tase as a result of a merger with israeli drug maker agis retrieved from httpsenwikipediaorgwindexphptitlealcobraoldid categories pharmaceutical companiespharmaceuticscompanies listed on nasdaqpharmaceutical companies of israelhidden categories pages using web citations with no urlarticles lacking reliable references from october all articles lacking reliable referencespages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  january  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی     한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info alcobra pharma home about our company management directors pipeline abusedeterrent amphetamine immediaterelease adair for adhd metadoxine extended release mdx for fragile x syndrome scientific posters  publications investors corporate governance financial information stock information investor faqs contact news  events contact alcobra relentlessly pursues creative unbeaten paths for the identification development and commercialization of therapeutics for impairing cns disorders we are committed to developing safe and effective products for the treatment of cognitive disorders includingadhd and fragile x syndrome view our corporate presentation previous next copyright  alcobra pharma alcobra  wikipedia alcobra from wikipedia the free encyclopedia jump to navigation search this article may rely excessively on sources too closely associated with the subject potentially preventing the article from being verifiable and neutral please help improve it by replacing them with more appropriate citations to reliable independent thirdparty sources october  learn how and when to remove this template message alcobra ltd type public company traded as nasdaq adhd industry pharmaceutical industry headquarters tel aviv israel products metadoxine extended release mdx website wwwalcobrapharmacom alcobra ltd is a public specialty pharmaceutical company the company is focused on the development of new medications to help patients with cognitive disorders including attention deficit hyperactivity disorder adhd and fragile x syndrome alcobra is headquartered in tel aviv israel and also has a us office located outside of philadelphia in plymouth meeting pennsylvania contents  company history  products in development  adhd  fragile x syndrome  references company historyedit alcobra was founded in  in  the company completed an initial public offering ipo and trades under the symbol “adhd” on the nasdaq stock exchange products in developmentedit metadoxine extended release mdx is the company’s lead investigational product candidate metadoxine extended release is a monoamineindependent modulator of gaba gammaaminobutyric acid transmission the mechanism of action does not directly affect dopamine or norepinephrine the compound is not a psychostimulant metadoxine has shown no potential for abuse or addiction in studies completed to date adhdedit alcobra has completed two phase ii trials and one phase iii trial of metadoxine extended release mdx in adults with adhd alcobra has also completed one phase ii adolescent adhd study of metadoxine extended release mdx in mid alcobra began a second phase iii trial of metadoxine extended release mdx in adults with adhd called the measure study fragile x syndromeedit in december  the fda granted orphan drug designation to metadoxine in the treatment of fragile x syndrome in june  alcobra completed a phase ii clinical trial of mdx for the treatment of adolescents and adults with fragile x syndrome in september  the fda granted “fast track” status to metadoxine extended release mdx for fragile x syndrome referencesedit  metadoxine extended release mdx for adult adhd alcobra ltd  retrieved    manor i benhayun r aharonperetz j salomy d weizman a daniely y meggido d newcorn jh biederman j adler la  a randomized doubleblind placebocontrolled multicenter study evaluating the efficacy safety and tolerability of extendedrelease metadoxine in adults with attentiondeficithyperactivity disorder journal of clinical psychiatry  – pmid  doijcpm   manor i rubin j daniely y adler la  attention benefits after a single dose of metadoxine extended release in adults with predominantly inattentive adhd postgrad med  – pmid  doipgm   weisler r adler la rubin j daniely y manor i  a phase  randomized doubleblind placebocontrolled study of metadoxine extended release  mg compared with placebo once daily in  adults with attentiondeficithyperactivity disorder  missing or empty url help  alcobras mdx meets primary endpoint in phase ii safety and tolerability clinical trial in adolescents with adhd alcobra ltd  retrieved    fda grants orphan drug status to metadoxine in fragile x syndrome alcobra ltd  retrieved    alcobra announces results from phase  clinical trial of mdx for fragile x syndrome alcobra ltd  retrieved    fda grants fast track designation to alcobras mdx for fragile x syndrome alcobra ltd  retrieved   v t e israeli companies traded on nasdaq healthcare alcobra biolinerx biondvax pharmaceutical compugen enzymotec given imaging kamada mazor robotics medigus oramed pharmaceuticals perrigo company pluristem therapeutics rewalk robotics rosetta genomics syneron medical communication  networks allot communications alvarion audiocodes b communications ceragon networks dsp group ezchip semiconductor gilat satellite networks internet gold golden lines orckit communications partner communications company radcom radvision rit technologies rr media software attunity bluephoenix solutions bos better online solutions check point software technologies clicksoftware technologies commtouch software cimatron cyberark formula systems  jacada magic software enterprises mind cti nice systems perion network radware sapiens international corporation nv verint systems wix electronics camtek ceva eltek kornit digital mellanox technologies nova measuring instruments orbotech solaredge tower semiconductor security  defense arotech elbit systems ituran location and control magal security systems pointer telocation rada electronic industries tat technologies consumer goods caesarstone sdotyam sodastream international conglomerates ampalamerican israel corporation elbit imaging isramco this company is americanbased but is traded on the tase as a result of a merger with israeli drug maker agis retrieved from httpsenwikipediaorgwindexphptitlealcobraoldid categories pharmaceutical companiespharmaceuticscompanies listed on nasdaqpharmaceutical companies of israelhidden categories pages using web citations with no urlarticles lacking reliable references from october all articles lacking reliable referencespages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  january  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view alcobra  wikipedia alcobra from wikipedia the free encyclopedia jump to navigation search this article may rely excessively on sources too closely associated with the subject potentially preventing the article from being verifiable and neutral please help improve it by replacing them with more appropriate citations to reliable independent thirdparty sources october  learn how and when to remove this template message alcobra ltd type public company traded as nasdaq adhd industry pharmaceutical industry headquarters tel aviv israel products metadoxine extended release mdx website wwwalcobrapharmacom alcobra ltd is a public specialty pharmaceutical company the company is focused on the development of new medications to help patients with cognitive disorders including attention deficit hyperactivity disorder adhd and fragile x syndrome alcobra is headquartered in tel aviv israel and also has a us office located outside of philadelphia in plymouth meeting pennsylvania contents  company history  products in development  adhd  fragile x syndrome  references company historyedit alcobra was founded in  in  the company completed an initial public offering ipo and trades under the symbol “adhd” on the nasdaq stock exchange products in developmentedit metadoxine extended release mdx is the company’s lead investigational product candidate metadoxine extended release is a monoamineindependent modulator of gaba gammaaminobutyric acid transmission the mechanism of action does not directly affect dopamine or norepinephrine the compound is not a psychostimulant metadoxine has shown no potential for abuse or addiction in studies completed to date adhdedit alcobra has completed two phase ii trials and one phase iii trial of metadoxine extended release mdx in adults with adhd alcobra has also completed one phase ii adolescent adhd study of metadoxine extended release mdx in mid alcobra began a second phase iii trial of metadoxine extended release mdx in adults with adhd called the measure study fragile x syndromeedit in december  the fda granted orphan drug designation to metadoxine in the treatment of fragile x syndrome in june  alcobra completed a phase ii clinical trial of mdx for the treatment of adolescents and adults with fragile x syndrome in september  the fda granted “fast track” status to metadoxine extended release mdx for fragile x syndrome referencesedit  metadoxine extended release mdx for adult adhd alcobra ltd  retrieved    manor i benhayun r aharonperetz j salomy d weizman a daniely y meggido d newcorn jh biederman j adler la  a randomized doubleblind placebocontrolled multicenter study evaluating the efficacy safety and tolerability of extendedrelease metadoxine in adults with attentiondeficithyperactivity disorder journal of clinical psychiatry  – pmid  doijcpm   manor i rubin j daniely y adler la  attention benefits after a single dose of metadoxine extended release in adults with predominantly inattentive adhd postgrad med  – pmid  doipgm   weisler r adler la rubin j daniely y manor i  a phase  randomized doubleblind placebocontrolled study of metadoxine extended release  mg compared with placebo once daily in  adults with attentiondeficithyperactivity disorder  missing or empty url help  alcobras mdx meets primary endpoint in phase ii safety and tolerability clinical trial in adolescents with adhd alcobra ltd  retrieved    fda grants orphan drug status to metadoxine in fragile x syndrome alcobra ltd  retrieved    alcobra announces results from phase  clinical trial of mdx for fragile x syndrome alcobra ltd  retrieved    fda grants fast track designation to alcobras mdx for fragile x syndrome alcobra ltd  retrieved   v t e israeli companies traded on nasdaq healthcare alcobra biolinerx biondvax pharmaceutical compugen enzymotec given imaging kamada mazor robotics medigus oramed pharmaceuticals perrigo company pluristem therapeutics rewalk robotics rosetta genomics syneron medical communication  networks allot communications alvarion audiocodes b communications ceragon networks dsp group ezchip semiconductor gilat satellite networks internet gold golden lines orckit communications partner communications company radcom radvision rit technologies rr media software attunity bluephoenix solutions bos better online solutions check point software technologies clicksoftware technologies commtouch software cimatron cyberark formula systems  jacada magic software enterprises mind cti nice systems perion network radware sapiens international corporation nv verint systems wix electronics camtek ceva eltek kornit digital mellanox technologies nova measuring instruments orbotech solaredge tower semiconductor security  defense arotech elbit systems ituran location and control magal security systems pointer telocation rada electronic industries tat technologies consumer goods caesarstone sdotyam sodastream international conglomerates ampalamerican israel corporation elbit imaging isramco this company is americanbased but is traded on the tase as a result of a merger with israeli drug maker agis retrieved from httpsenwikipediaorgwindexphptitlealcobraoldid categories pharmaceutical companiespharmaceuticscompanies listed on nasdaqpharmaceutical companies of israelhidden categories pages using web citations with no urlarticles lacking reliable references from october all articles lacking reliable referencespages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  january  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view